We will recruit a large population of HIV infected individuals in various stages of disease by contacting physicians, appropriate medical, public health and community organizations. All have already given written agreement to encourage patients to participate in the project. Consent will be obtained for enrollment and the collection of clinical and laboratory data. Confidentiality will be assured by a system of coding. We will then perform initial medical examinations and obtain routine laboratory data on all patients participating in the project. Specimens for immunologic and virologic assessment and banking will be collected and separated in the General Clinical Research Center (GCRC). This data and that obtained in scheduled follow- up visits will be entered into the GCRC's CLINFO database in sequential fashion over the entire duration of the study. This database will define the natural history of HIV infection in our population. Based on the initial clinical and laboratory studies, patients and specimens will be triaged to specific protocols (Projects 2, 3 and 5) which will evaluate therapeutic interventions of HIV infection or study basic questions concerning the pathogenesis of AIDS. Patients will have rapid access to state-of- the-art medical care. When they develop opportunistic infections, they will be enrolled in therapeutic protocols, if available, or treated with standard therapy. All information will be included in the database.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Brashers, Dale E; Basinger, Erin D; Rintamaki, Lance S et al. (2017) Taking Control: The Efficacy and Durability of a Peer-Led Uncertainty Management Intervention for People Recently Diagnosed With HIV. Health Commun 32:11-21
Peterson, Jennifer L; Rintamaki, Lance S; Brashers, Dale E et al. (2012) The forms and functions of peer social support for people living with HIV. J Assoc Nurses AIDS Care 23:294-305
Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Raboud, Janet M; Diong, Christina; Carr, Andrew et al. (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11:39-50
Williams, Pl; Wu, Jw; Cohn, Se et al. (2009) Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 10:290-301
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Sax, Paul E; Tierney, Camlin; Collier, Ann C et al. (2009) Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361:2230-40
Ma, Qing; Forrest, Alan; Rosenkranz, Susan L et al. (2008) Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 29:91-101
Collier, Ann C; Tierney, Camlin; Downey, Gerald F et al. (2008) Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. HIV Clin Trials 9:91-102
Demeter, Lisa M; DeGruttola, Victor; Lustgarten, Stephanie et al. (2008) Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 9:11-25

Showing the most recent 10 out of 97 publications